Learn More

About Us


ProLynx is a limited liability company registered in California, founded in 2010 and led by Daniel V. Santi, M.D., Ph.D. and Gary W. Ashley, Ph.D.

Daniel V. Santi, M.D., Ph.D., Founder and President. Dr. Santi received a Ph.D. in Medicinal Chemistry from SUNY in 1967 and a M.D. from UCSF in 1981.  He was Assistant Professor of Chemistry at UCSB from 1968 to 1974.  He joined the UCSF faculty in 1974 and was Professor of Biochemistry and Biophysics, and of Pharmaceutical Chemistry at UCSF until 2000 when he became CEO of Kosan Biosciences.  He returned to UCSF in 2007 where he served as interim Director of the Clinical and Translational Science Institute and then Director of Translational Research at QB3. He became an Associate Dean fo External Relationships in 2009, and has managed a successful Industry Outreach Program since that time.  Dr. Santi has published over 300 scientific papers and is co-inventor on over 40 US patents.

Dan Santi was a member of the original Scientific Advisory Board of Chiron Corp. and has co-founded five biotechnology companies. In 1988, he founded and was Chairman of the peptide-combinatorial chemistry company Protos Corp., which merged with Chiron in 1992.  He was a co-founder of Parnassus Pharmaceuticals, and of Prospect Genomics that merged with Structural Genomix in 2001.  In 1996, he co-founded Kosan Biosciences where he served as CEO and Chairman until 2006; Kosan was acquired by Bristol Myers Squibb.  During his tenure as CEO the company went public (NASDAQ), and four oncology compounds were brought into clinical trials.  He co-founded the platform technology company ProLynx LLC in 2010, where he currently serves as President.

Gary W. Ashley, Ph.D., Founder and Chief Scientific Officer.  Dr. Ashley was a Assistant Professor of Chemistry at Northwestern University, head of Chemistry at Parnassus Pharmaceuticals, Executive Director of Chemistry and then Vice President, Exploratory Research at Kosan Biosciences, Inc.  Dr. Ashley is also a licensed patent agent with over five years professional experience.  He is co-author of over 40 scientific publications, and co-inventor on over 35 issued patents.

Usha Arunachalam, Ph.D., MBA, VP Business Development.  Dr. Arunachalam received her Ph.D. in Biochemistry from the Indian Institute of Science, Bangalore, India and her MBA from UCLA's Anderson School of Management.

Dr. Usha Arunachalam brings to Prolynx about 20 years of business development experience, primarily with early-staged biotechnology companies.  She has held senior management positions in various biotechnology companies.  Most recently she was Vice President of Business Development and Alliance Management for Research at the Leukemia, Lymphoma Society.  Notably, she was Vice President of Business Development and led the business development and strategic efforts during the formative years of Five Prime Therapeutics.  Here, she was an integral member of the executive team and was instrumental in raising more than $ 120 MM in near term investments for collaborative research from strategic partners.  Prior to FivePrime she was VP of Business Development at Intrabiotics, Sr. Director, Business Development at Kosan Biosciences and Associate Director at Chiron Corporation.  Dr. Arunachalam serves on the board of The Pacific Vision Foundation.